Compare Novo Nordisk A/S (NVO) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Novo Nordisk A/S trades at $44.89 (market cap $200.69B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $211.72 (market cap $39.88B). The key difference: Novo Nordisk A/S is far larger — about 5× TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock's market cap, and Novo Nordisk A/S pays a 3.98% dividend while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock pays none. Which is the better fit depends on your goals.
| NVO | TTWO | |
|---|---|---|
Market Cap | $200.69B | $39.88B |
Sector | Health | Media |
52-Week High | $63.98 | $262.29 |
52-Week Low | $35.29 | $189.69 |
Enterprise Value | $215.49B | $41.00B |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Take-Two Interactive trades at $213.29, down 0.65% amid bearish technical signals despite strong analyst support. The stock shows negative profitability with a -4.79% net margin and -$4.48B net loss for 2025, though recent earnings beats and GTA 6's November launch anticipation provide catalysts. Cash flow improved to $457M net inflow in 2025 from prior deficits, while debt-to-asset ratio rose to 39.87%.
Outlook hinges on GTA 6's execution, with 79% analyst buy ratings and $302.60 price target suggesting 42% upside. Risks include high valuation multiples (P/S 5.91, EV/EBITDA 32.78) and reliance on single-title success. Near-term volatility may persist pending Q3 earnings and preorder trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
